Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

NCT00050232 is registered in ClinicalTrials.gov with Avanir Pharmaceuticals as lead sponsor.

NCT NCT00050232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00050232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Lead sponsor
Avanir Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2002
Completion date
June 30, 2004
Enrollment
96
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis